Yoshio Ogawa

Yoshio Ogawa

Auto-generated profile, based on publicly available information

Yoshio Ogawa

Department of Urology, Showa University School of Medicine

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
KKKuniko Kusama-Eguchi
Kuniko Kusama-Eguchi
TMTakaaki Miyano
Takaaki Miyano
MYMakoto Yamamoto
Makoto Yamamoto
ASAtsuhiro Suda
Atsuhiro Suda
YIYoshihisa Ito
Yoshihisa Ito
TKTadashi Kusama
Tadashi Kusama

14 August 2019 in Diagnostics
Verified
Journal Article
Open access
PDF file
NMNaoe Michio
Naoe Michio
CKChiho Kusaka
Chiho Kusaka
MOMika Ohta
Mika Ohta
YHYuki Hasebe
Yuki Hasebe
TUTsutomu Unoki
Tsutomu Unoki
HIHikaru Ishii
Hikaru Ishii
Purpose: Liquid biopsy is becoming increasingly important as a guide for selecting new drugs and determining their efficacy. In urological cancer, serum markers for renal cell and urothelial cancers has made the development of liquid biopsy for these cancers strongly desirable. Liquid biopsy is less invasive than conventional tissue biopsy is, enabling frequent biopsies and, therefore, is considered effective for monitoring the treatment course. Circulating tumor cells (CTCs) are a representative liquid biopsy specimen. In the present study, we focused on developing our novel technology for capturing renal cell cancer (RCC)-CTCs using an anti-G250 antibody combined with new devices. Basic experiments of our technology showed that it was possible to detect RCC-CTC with a fairly high accuracy of about 95%. Also, RCC-CTC was identified in the peripheral blood of actual RCC patients. Additionally, during the treatment course of the RCC patient, change in the number of RCC-CTC was confirmed in one case. We believe that the technology we developed will be useful for determining the treatment efficacy and drug selection for the treatment of renal cell cancer (RCC). In order to solve issues such as thresholds setting of this technology, large-scale clinical trials are expected.

1 January 2018 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
TNTakehiko Nakasato
Takehiko Nakasato
AHAya Hiramatsu
Aya Hiramatsu
YMYuki Matsui
Yuki Matsui
TUTsutomu Unoki
Tsutomu Unoki
HSHideaki Shimoyama
Hideaki Shimoyama
YOYoshio Ogawa
Yoshio Ogawa
Upper urinary tract neuroendocrine carcinoma (UUT-NEC) is extremely rare and has a poor prognosis. Although a few cases of successful treatment have been reported, no treatment has shown established efficacy. We analyzed 70 UUT-NEC patients, including 68 with small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC) reported between 1985 and 2017 and 2 treated at our hospital. Median patient age was 66 years, 58.6% were men, and 60% were of Asian descent. Most UUT-NECs were SCNEC (68; 95.7%), whereas LCNEC was very rare (2; 2.9%). More than half of the patients had accompanying other histological components, the most common being urothelial carcinoma (51.5%), whereas 41.4% had NEC alone. Of the 70 patients, 27 underwent additional therapy (e.g., chemotherapy and radiotherapy) along with surgery. Median survival was 15 months. In univariate analysis, stages T1-2 disease showed better prognosis than stages T3-4 (P < 0.001). Additional treatment (e.g., chemotherapy and radiotherapy) significantly improved prognosis (P = 0.014). Moreover, platinum-based chemotherapy also was associated with improved prognosis (P = 0.017). For platinum-based chemotherapy, multicollinearity with additional treatments was strong, and, thus, these data were not included in the analysis. Multivariate analysis revealed pathological stage (T1-2 vs. T3-4; P = 0.003) and additional treatment (P = 0.028) to be independent predictors of improved prognosis. Although UUT-NEC has a poor prognosis, additional treatment along with surgery and therapeutic intervention and stage T1-2 disease are independent factors to improve prognosis.

27 October 2004 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
MNMichio Naoe
Michio Naoe
YOYoshio Ogawa
Yoshio Ogawa
KFKhozo Fuji
Khozo Fuji
TFTakashi Fukagai
Takashi Fukagai
KIKatsuki Inoue
Katsuki Inoue
HYHideki Yoshida
Hideki Yoshida

1 January 2020 in Urology Research and Practice
Verified
Journal Article
Closed access
SNSat Prasad Nepal
Sat Prasad Nepal
TNTakehiko Nakasato
Takehiko Nakasato
YOYoshio Ogawa
Yoshio Ogawa
MNMichio Naoe
Michio Naoe
TSTakeshi Shichijo
Takeshi Shichijo
MOMadoka Omizu
Madoka Omizu
Objective: This study aimed to assess the relationship of the prostate cancer and Gleason scores (GSs) or ISUP Grade system with prostate volume (PV) as assessed by magnetic resonance imaging (MRI) cognitive biopsy and standard biopsy. Material and methods: Data were collected from 659 patients who underwent MRI cognitive biopsy and standard biopsy from January 2014 to January 2018. The biopsies were performed because of increased prostate-specific antigen (PSA) levels (>4 ng/mL) and/or abnormal digital rectal examination findings. Transrectal ultrasound was used to measure PV. Results: Prostate cancer detection rates in patients with increased PVs of ≤40 cc and >40 cc were 68.8% and 51.6% (p40 cc were 68% and 73%, and 22.3% and 37.8%, respectively, for those with ISUP Grade group ≥4 (Gleason score ≥8) (p=0.003). Among the patients with PV>40 cc, univariate logistic regression showed a significant relationship between ISUP Grade group ≥2 and PSA, free/total PSA, PSA density, and MRI (p40 cc. Conclusion: Although the detection rates of prostate cancer decreased as PV increased, the detection of prostate cancer aggressiveness increased as PV increased. This increase in high ISUP Grade lesions with the rise in PV is due to the use of MRI during prostate biopsy with standard biopsy. Cite this article as: Nepal SP, Nakasato T, Ogawa Y, Naoe M, Shichijo T, Maeda Y, et al. Prostate cancer detection rate and Gleason score in relation to prostate volume as assessed by magnetic resonance imaging cognitive biopsy and standard biopsy. Turk J Urol 2020; 46(6): 449-54.

15 June 2022 in Medicina
Verified
Journal Article
Open access
PDF file
TITatsuki Inoue
Tatsuki Inoue
MTMana Tsukada
Mana Tsukada
YTYoshiki Tsunokawa
Yoshiki Tsunokawa
YMYoshiko Maeda
Yoshiko Maeda
SFSeiya Fukuoka
Seiya Fukuoka
MASATAKA SUNAGAWAMASATAKA SUNAGAWA
MASATAKA SUNAGAWA
Background and Objectives: The Japanese herbal medicine Yokukansan (YKS) has analgesic properties and is used for various pain disorders. The purpose of the present study was to investigate the effects of YKS in Hunner-type interstitial cystitis (HIC) using an experimental rat model of HIC and to explore its antioxidant activity and role as the underlying mechanism of action. Materials and Methods: The antioxidant capacity of YKS was evaluated by determining its hydroxyl radical (·OH) scavenging capacity using electron spin resonance (ESR). Next, the effects of YKS administration were explored using a toll-like receptor-7 agonist-induced rat model of HIC. The von Frey test was performed to assess bladder pain. Three days after HIC induction, the bladder was removed, and the expression of oxidative stress parameters in the bladder wall was investigated (reactive oxygen metabolites (ROMs), ·OH, and 8-hydroxy-2’-deoxyguanosine (8-OhdG)). Results: YKS had a ·OH scavenging capacity according to the ESR study. In the von Frey test, a significant decrease in the withdrawal threshold was observed in the HIC group compared with the control group; however, the decrease was ameliorated by the administration of YKS. Oxidative stress parameters showed increasing tendencies (ROMs test and 8-OHdG) or a significant increase (·OH) in the HIC group compared with the control group; however, the increase was significantly suppressed by the administration of YKS. Conclusions: These findings suggest that YKS is effective against HIC and that its antioxidant activity is involved in the mechanism of action.